| dbo:abstract |
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza (Nusinersen), Tegsedi (Inotersen), and Waylivra (Volanesorsen) and has 4 drugs in pivotal studies: tominersen for Huntington’s disease, tofersen for SOD1-ALS, AKCEA-APO(a)-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis. The company was named Isis Pharmaceuticals until December 2015. (en) La Ionis Pharmaceuticals (conosciuta anche come Isis Pharmaceuticals fino al dicembre 2015) è un'azienda statunitense fondata nel 1989 con sede a Carlsbad, in California. L'azienda è attiva nel settore farmaceutico con più di 35 medicinali in produzione tra cui quelli per la riduzione della huntingtina (IONIS-HTTRx) nei soggetti affetti dalla malattia di Huntington e per la cura della atrofia muscolare spinale . Vengono prodotti anche farmaci per la riduzione dei livelli di colesterolo. L'azienda è stata fondata da Stanley T. Crooke, ex esponente di GlaxoSmithKline, al fine di commercializzare la . (it) |
| dbo:assets |
3.233E9 (dbd:usDollar) |
| dbo:equity |
1.684E9 (dbd:usDollar) |
| dbo:formerName |
Isis Pharmaceuticals, Inc. (en) |
| dbo:foundingYear |
1989-01-01 (xsd:gYear) |
| dbo:headquarter |
dbr:Carlsbad,_California |
| dbo:industry |
dbr:Biotechnology |
| dbo:keyPerson |
dbr:CEO dbr:Chairperson dbr:CFO dbr:Joseph_Loscalzo |
| dbo:netIncome |
2.94E8 (dbd:usDollar) |
| dbo:numberOfEmployees |
660 (xsd:nonNegativeInteger) |
| dbo:product |
dbr:Volanesorsen dbr:Mipomersen dbr:Nusinersen dbr:Plazomicin dbr:Inotersen |
| dbo:revenue |
1.122E9 (dbd:usDollar) |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Ionis_Pharmaceuticals.svg?width=300 |
| dbo:type |
dbr:Public_company |
| dbo:wikiPageExternalLink |
https://www.ionispharma.com |
| dbo:wikiPageID |
48885758 (xsd:integer) |
| dbo:wikiPageLength |
16764 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1120651737 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Carlsbad,_California dbr:Biogen dbc:Huntington's_disease dbr:Antisense_therapy dbr:University_of_Massachusetts dbr:Volanesorsen dbc:Biotechnology_companies_established_in_1989 dbr:RNA_interference dbr:Public_company dbc:Biotechnology_companies_of_the_United_States dbc:Companies_listed_on_the_Nasdaq dbr:Corporate_spin-off dbr:Amyloidosis dbr:Genta_(company) dbr:Regulus_Therapeutics dbr:Cold_Spring_Harbor_Laboratory dbr:Genzyme dbr:Gilead_Sciences dbr:GlaxoSmithKline dbr:Mipomersen dbr:Monoclonal_antibody_therapy dbc:Spinal_muscular_atrophy dbr:CEO dbr:Drug_discovery dbr:AIDS dbr:ALS dbr:Alicaforsen dbr:Alnylam_Pharmaceuticals dbr:Cytomegalovirus_retinitis dbr:Drug_development dbr:European_Medicines_Agency dbr:Familial_hypercholesterolemia dbr:Fomivirsen dbr:Food_and_Drug_Administration dbr:Novartis dbr:Nusinersen dbr:Cardiovascular_disease dbr:RNA dbc:Health_care_companies_based_in_California dbr:Islamic_State_of_Iraq_and_the_Levant dbr:Huntingtin dbr:Hydrolysis dbc:Antisense_RNA dbc:Companies_based_in_Carlsbad,_California dbr:Biotechnology dbr:Immunocompromised dbr:Plazomicin dbr:HAART dbr:Inotersen dbr:Chairperson dbr:CFO dbr:Genital_warts dbr:Liver_disease dbr:Investigational_new_drug dbr:Hybridon dbr:Oligomers dbr:Drug_target dbr:Russell_1000 dbr:Micro-RNA dbr:Huntington’s_disease dbr:Joseph_Loscalzo |
| dbp:assets |
3.233E9 (dbd:usDollar) |
| dbp:bloomberg |
IONS:US (en) |
| dbp:equity |
1.684E9 (dbd:usDollar) |
| dbp:formerName |
Isis Pharmaceuticals, Inc. (en) |
| dbp:founder |
Stanley T. Crooke (en) |
| dbp:google |
IONS:NASDAQ (en) |
| dbp:hqLocation |
Carlsbad, California, U.S. (en) |
| dbp:industry |
dbr:Biotechnology |
| dbp:keyPeople |
dbr:Joseph_Loscalzo (en) Brett P. Monia (en) Elizabeth L. Hougen (en) |
| dbp:logo |
Ionis_Pharmaceuticals.svg (en) |
| dbp:name |
Ionis Pharmaceuticals, Inc. (en) |
| dbp:netIncome |
2.94E8 (dbd:usDollar) |
| dbp:numEmployees |
660 (xsd:integer) |
| dbp:products |
dbr:Volanesorsen dbr:Mipomersen dbr:Nusinersen dbr:Plazomicin dbr:Inotersen |
| dbp:revenue |
(en) 1.122E9 (dbd:usDollar) |
| dbp:secCik |
874015 (xsd:integer) |
| dbp:symbol |
IONS (en) |
| dbp:type |
dbr:Public_company |
| dbp:website |
https://www.ionispharma.com |
| dbp:wikiPageUsesTemplate |
dbt:Advert dbt:Authority_control dbt:Increase dbt:Infobox_company dbt:Multiple_issues dbt:Reflist dbt:Short_description dbt:Start_date_and_age dbt:Ubl dbt:Update dbt:Which dbt:Finance_links |
| dbp:yahoo |
IONS (en) |
| dct:subject |
dbc:Huntington's_disease dbc:Biotechnology_companies_established_in_1989 dbc:Biotechnology_companies_of_the_United_States dbc:Companies_listed_on_the_Nasdaq dbc:Spinal_muscular_atrophy dbc:Health_care_companies_based_in_California dbc:Antisense_RNA dbc:Companies_based_in_Carlsbad,_California |
| rdf:type |
owl:Thing dbo:Company schema:Organization dul:Agent dul:SocialPerson dbo:Agent wikidata:Q24229398 wikidata:Q43229 wikidata:Q4830453 dbo:Organisation |
| rdfs:comment |
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza (Nusinersen), Tegsedi (Inotersen), and Waylivra (Volanesorsen) and has 4 drugs in pivotal studies: tominersen for Huntington’s disease, tofersen for SOD1-ALS, AKCEA-APO(a)-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis. The company was named Isis Pharmaceuticals until December 2015. (en) La Ionis Pharmaceuticals (conosciuta anche come Isis Pharmaceuticals fino al dicembre 2015) è un'azienda statunitense fondata nel 1989 con sede a Carlsbad, in California. L'azienda è attiva nel settore farmaceutico con più di 35 medicinali in produzione tra cui quelli per la riduzione della huntingtina (IONIS-HTTRx) nei soggetti affetti dalla malattia di Huntington e per la cura della atrofia muscolare spinale . Vengono prodotti anche farmaci per la riduzione dei livelli di colesterolo. (it) |
| rdfs:label |
Ionis Pharmaceuticals (en) Ionis Pharmaceuticals (it) |
| owl:sameAs |
yago-res:Ionis Pharmaceuticals wikidata:Ionis Pharmaceuticals http://arz.dbpedia.org/resource/ايونيس_للادويه dbpedia-fa:Ionis Pharmaceuticals dbpedia-it:Ionis Pharmaceuticals https://global.dbpedia.org/id/26LzE |
| skos:closeMatch |
http://www.grid.ac/institutes/grid.282569.2 |
| prov:wasDerivedFrom |
wikipedia-en:Ionis_Pharmaceuticals?oldid=1120651737&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Ionis_Pharmaceuticals.svg |
| foaf:homepage |
https://www.ionispharma.com |
| foaf:isPrimaryTopicOf |
wikipedia-en:Ionis_Pharmaceuticals |
| foaf:name |
Ionis Pharmaceuticals, Inc. (en) |
| is dbo:institution of |
dbr:C._Frank_Bennett |
| is dbo:wikiPageDisambiguates of |
dbr:Ionis |
| is dbo:wikiPageRedirects of |
dbr:Ionis_pharmaceutical dbr:Isis_Pharmaceutical dbr:Isis_Pharmaceuticals |
| is dbo:wikiPageWikiLink of |
dbr:Priority_review dbr:Biogen dbr:Breakthrough_Prize_in_Life_Sciences dbr:Antisense_therapy dbr:Huntington's_disease dbr:Volanesorsen dbr:List_of_pharmaceutical_companies dbr:Ionis dbr:Gene_therapy dbr:Genta_(company) dbr:National_Organization_for_Rare_Disorders dbr:Gilead_Sciences dbr:Mipomersen dbr:N-Lorem dbr:BB_Biotech dbr:Alexander_disease dbr:Alicaforsen dbr:Alnylam_Pharmaceuticals dbr:Fine_chemical dbr:Fomivirsen dbr:Nusinersen dbr:Discovery_and_development_of_gliflozins dbr:Fondazione_Roma dbr:Janssen_Pharmaceuticals dbr:Adrian_Krainer_(scientist) dbr:C._Frank_Bennett dbr:Human_genetic_enhancement dbr:Russell_1000_Index dbr:Name_changes_due_to_the_Islamic_State dbr:Ionis_pharmaceutical dbr:Isis_Pharmaceutical dbr:Isis_Pharmaceuticals |
| is dbp:workplaces of |
dbr:C._Frank_Bennett |
| is foaf:primaryTopic of |
wikipedia-en:Ionis_Pharmaceuticals |
